Home
overview

This conference will cover diseases associated with the skin such as melanoma, acne, psoriasis, dermatitus, urticaria (Hives), nail disorders and pigmentation. Despite generic and over-the-counter competition, the market for prescription dermatological products offers some significant sales opportunities. The role of biotechnology in the development of new drug delivery systems and genetic-based interventions is now of increasing importance.

Key issues the conference will discuss

Advances in the treatment of immune-mediated and inflammatory skin diseases

Photodynamic Therapy (PDT) and Photodynamic Diagnosis (PD) for malignant skin disorders

Reversing skim damage caused by sunlight

Antibodies targetting memory effector cells

Combinatorial Antibody Library Technology, "CoALT", generated anti-complement antibody

Treatment of chronic skin wounds

Non-viral transfection of human skin cells

Confirmed Speakers:

Professor Anton Stuetz, Head, Inflammatory Skin Diseases, Novartis

Dr Michael Reusch, Director, Clinical Research, Fujisawa Europe

Dr Chris Roberts, Clinical Research Director, Smith and Nephew

Dr Kjetil Hestdal, Vice President, Research & Development, PhotoCure

Dr Jean Rumsfield, Director, New Product Planning & Licensing, Fujisawa Healthcare

Dr Elena Rizova, Associate Director Medical Affairs, Dermatology, Biogen

Dr Rene Goedkoop, Clinical Director, Modex Therapeutics

Dr Andreas Goppelt, Chief Scientific Officer, Switch

Edward Connor, Vice President Clinical Development, MedImmune

Dr Paul Kemp, Chief Executive Officer, Intercytex

Dr Michael Davies, Clinical Director, Renovo

Dr Stephen Squinto, Executive Vice President, Head, Research, Alexion Pharmaceuticals

Professor Thomas Luger, Chairman, Dermatology, University of Münster

Professor Richard Groves, Head, Academic Dermatology, Imperial College of Science, Technology and Medicine

Professor Richard Camp, Head, Dermatology, University of Leicester

Comments from Previous SMi Pharmaceutical Conference Delegates


‘a cutting edge program’ Dr Kjetil Hestdal, Photocure
‘very interesting … an excellent overview of what is going on in modern dermatotherapy’ Professor Thomas Luger, Chairman, Dermatology, University of Münster

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Prof Richard Groves

Prof Richard Groves, Professor of Dermatology, Imperial College

9:10 OVERVIEW

Prof Thomas Luger

Prof Thomas Luger, Director & Chairman, Dermatology, University of Münster

  • Advances in the treatment of immune-mediated and inflammatory skin diseases
  • New biological response modifiers
  • Antibody fusion proteins
  • Antigen-pulsed dendritic cells for melanoma therapy
  • Future directions
  • 9:40 A NOVEL SMALL MOLECULE DRUG FOR AK & NMSC PEP005

    Garry Redlich

    Garry Redlich, Managing Director and Chief Executive Officer, Peplin Biotech

  • Structure & class
  • Drug action
  • Mechanism of action
  • Pilot clinical study
  • Clinical development plans
  • Licensing program
  • 10:20 PHOTODYNAMIC THERAPY (PDT) AND PHOTODYNAMIC DIAGNOSIS (PD) FOR MALIGNANT SKIN DISORDERS

    Dr Hilde Morris

    Dr Hilde Morris, , PhotoCure

  • Metvix® PDT - how does it work?
  • Selective accumulation in cancerous cells
  • Potential for photodynamic diagnosis (PD)
  • Clinical experience of Metvix® PDT in treatment of BCC and AK
  • Advantages regarding patient preference
  • 11:00 Morning Coffee

    11:20 REVERSING SKIN DAMAGE CAUSED BY SUNLIGHT

    Leanne West, Manager

    Leanne West, Manager, Technical & Clinical Affairs UK/Europe, Novogen

  • Effect on skin reddening and underlying damage leading to skin cancer
  • Effect of sunlight on immune response
  • Effect of NV-07a on sunlight-induced reduced immune response of skin allergic patients
  • WHO alert on limitations of sun blocks regarding melanoma
  • Clinical development programme
  • Commercial potential of NV-07a for after-sun skin repair
  • 12:00 KERATINOCYTE CELL SIGNALLING

    Prof Nick Reynolds

    Prof Nick Reynolds, Professor, Dermatology, University of Newcastle-upon-Tyne

  • Regulation of keratinocyte growth and differentiation by calcineurin and PKC
  • Abnormalities of PKC and NFAT signalling in psoriasis
  • Inhibition of keratinocyte calcineurin signalling by ciclosporin and tacrolimus
  • 12:40 Networking Lunch

    14:00 TOPICAL IMMUNOMODULATORS (TIMs)

    Dr Michael Reusch

    Dr Michael Reusch, Director, Clinical Research, Fujisawa

  • Eczema today – causes, prevalence, and therapeutic needs
  • Steroid-free vs steroid-sparing therapy
  • Protopic – a highly effective steroid-free therapy option for eczema
  • The TIM class is skin-selective and safe
  • ‘’Treat and prevent’’ – a new therapeutic paradigm in eczema
  • Health economics of Protopic
    Positioning within primary health care
    Long-term lessons to be learned
  • 14:40 CALCINEURIN INHIBITORS

    Prof Anton Stuetz, Head

    Prof Anton Stuetz, Head, Translational Medicine & Late Phase Products, Novartis

  • Effect on cytokine release from T and mast cells
  • Skin selective profile when delivered topically and orally
  • Anti-inflammatory effect
  • Advantages over alternative treatments
  • Discovery and recent developments
  • Results with eczema and psoriasis
    Approaches to marketing of non-steroid anti-inflammatories
  • 15:20 Afternoon Tea

    15:40 ISATX247 A NOVEL CALCINEURIN INHIBITOR

    Dr Randall Yatscoff

    Dr Randall Yatscoff, President & Chief Operating Officer, Isotechnika

  • ISATX247 is a novel calcineurin inhibitor
  • Preclinical and phase I trials indicate that ISATX247 is more potent and less toxic than CSA
  • Phase II trial of ISATX247 for treatment of moderate to severe psoriasis
  • 200 patients/80 patients 1.5 mg/kg/d/bid ISATX247; 80 patients 0.5 mg/kg/d/bid ISATX247; 40 patients on placebo
  • 3 month duration
  • Trial results to be reported
  • 16:20 NOVEL APPROACH TO DRUG TARGET IDENTIFICATION

    Dr Andreas Goppelt

    Dr Andreas Goppelt, Chief Scientific Officer, SWITCH Biotech

  • Limitations of conventional therapies in psoriasis
  • Identification of molecular switch genes in normal skin tissue
  • Target genes for wound healing and dermatological disorders
  • Real time PCR for target gene verification
  • Use of expression vectors and recombinant proteins to ‘jack up’ genetic activity
  • Application of technology to psoriasis, atopic dermatitis, vitiligo and chronic wounds
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Prof Richard Camp

    Prof Richard Camp, Professor of Dermatology, University of Leicester

    9:10 TARGETING MEMORY-EFFECTOR T CELLS

    Dr Elena Rizova

    Dr Elena Rizova, Associate Director, Medical Affairs, Biogen

  • Role of T cells in pathogenesis of psoriasis
  • Biologic strategies for treating psoriasis
  • Mode of action of alefacept (Amevive) (specific targeting of CD45Ro+ T memory-effector cells)
  • Clinical trials
  • Effect on treatment of psoriasis
  • Durability of remission
  • 9:40 INHIBITION OF COMPLEMENT IN THE TREATMENT OF DERMATOMYOSITIS

    Dr Stephen Squinto

    Dr Stephen Squinto, Executive Vice President, Head, Research, Alexion Pharmaceuticals

  • Limitations of current treatments of dermatomyositis
  • Antibody/complement component in dermatomyositis
  • Eculizamab; anti-C5 monoclonal antibody
  • Complement blockade in disease models
  • Advantages of anti-complement therapy in dermatomyositis
  • Dermatomyositis clinical trial results with Eculizamab
  • 10:20 NEW TREATMENTS FOR FUNGAL INFECTIONS

    Prof Rod Hay

    Prof Rod Hay, Chairman, International Foundation of Dermatology

  • New drugs - triazoles, cell wall inhibitors
  • Combination therapy
  • Future developments eg melanin biosynthesis inhibitors
  • Drug resistance
  • 11:00 Morning Coffee

    11:20 NEW DEVELOPMENT FOR ACNE

    Dr Jean Rumsfield

    Dr Jean Rumsfield, Director, New Product Planning & Licensing, Fujisawa

  • Potent antibiotic and independent anti-inflammatory activity
  • New proprietary SMP topical drug delivery
  • Reduction of inflammatory lesions
  • Phase III studies
  • Comparison with other treatments
  • 12:00 TRANSFER OF LIVING SKIN CELLS TO WOUND BED

    Prof Sheila MacNeil

    Prof Sheila MacNeil, Director, CellTran

  • Surgical needs and marketing opportunities
  • Plasma technology for carrier devices
  • Advantages of CellTran approach
  • Patient benefits as shown by clinical trials
  • Ultimate goals
  • 12:40 Networking lunch

    13:00 TREATMENT OF CHRONIC SKIN WOUNDS

    Dr Rene Goedkoop

    Dr Rene Goedkoop, Clinical Director, Modex Therapeutics

  • Product description
  • Results of clinical trials
  • Complement to EpiDex™
  • 14:40 CELL-BASED THERAPEUTIC SOLUTIONS FOR TREATMENT OF SKIN FAILURE

    Dr Paul Kemp

    Dr Paul Kemp, Chief Executive Officer, Intercytex

  • Advantages of second generation cell therapeutic products
  • Market for tissue engineered skin
  • Technological and regulatory hurdles to be overcome
  • 15:20 Afternoon Tea

    15:40 IDENTIFICATION OF NOVEL THERAPEUTICS FOR THE TREATMENT OF CHRONIC ULCERS

    Dr Michaela Bittner

    Dr Michaela Bittner, Associate Director, Research & Development, SWITCH Biotech

  • Gene profiling in tissue
  • Functional studies in cell culture
  • Target validation in animal models
  • 16:20 LIVING HUMAN DERIVED DERMAL REPLACEMENT

    Dr Christopher Roberts

    Dr Christopher Roberts, Director, Clinical Research, Smith & Nephew

  • Other chronic wound experiences
  • Foot ulcers in diabetes
  • Culture of human dermal fibroblasts into a biosynthetic scaffold
  • Generation of 3-dimensional human dermis containing metabolically active living cells
  • Safety features
  • New developments
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.